Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCB 2020S

Next Previous
Drug Profile

SCB 2020S

Alternative Names: B.1.351 S-Trimer vaccine - Clover Biopharmaceuticals; Endemic coronavirus vaccine - Clover Biopharmaceuticals; Multiple variants SARS-CoV-2 vaccine - Clover Biopharmaceuticals; Multivalent SARS-COV2 vaccine - Clover Biopharmaceuticals; SARS-CoV-2 S-Trimer B.1.351 variant vaccine - Clover Biopharmaceuticals; SCB-2020-S

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clover Biopharmaceuticals
  • Class COVID-19 vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in South Africa (IM)
  • 23 Apr 2023 Clover Biopharmaceuticals completes phase I trial in COVID-2019 infections (Prevention) in South Africa (IM) (NCT05228314)
  • 31 May 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in South Africa (IM) (NCT05228314)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top